Enhanced vascular chymase-dependent conversion of endothelin in the diabetic kidney

Ochsner Journal

Volumn 13, Issue 1, 2013, Pages 49-55

  Harrison Bernard, Lisa M ^a   de Garavilla, Lawrence ^b   Bivona, Benjamin J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Chymases; Diabetic nephropathies; Endothelin 1; Kidney failure; Vasoconstriction

Indexed keywords

CHYMASE; CHYMASE INHIBITOR; ENDOTHELIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME INHIBITION; EXPERIMENTAL STUDY; IN VITRO STUDY; KIDNEY ARTERY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS;

EID: 84875199260     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Park S, Bivona BJ, Ford JS, et al. Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature. Hypertension. 2013 Feb; 61(2):465-471. Epub 2012 Dec 3.
2. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011 Jun 22;305(24):2532-2539.
3. Bays HE, Bazata DD, Clark NG, et al. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). BMC Public Health. 2007 Oct 3;7:277.
4. National Diabetes Information Clearinghouse (NDIC). National Diabetes Statistics, 2011. NIH Publication No. 11-3892. February 2011. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.aspx Accessed September 21, 2012.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16; 287(3):356-359.
6. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411-415.
7. Madeddu P, Troffa C, Glorioso N, et al. Effect of endothelin on regional hemodynamics and renal function in awake normotensive rats. J Cardiovasc Pharmacol. 1989 Dec;14(6): 818-825.
8. Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002 Nov;15(11): 967-972.
9. Peppa-Patrikiou M, Dracopoulou M, Dacou-Voutetakis C. Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors. Metabolism. 1998 Nov;47(11):1408-1412.
10. Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care. 1994 Apr;17(4):263-266.
11. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int. 2000 Oct;58(4):1534-1545.
12. Wenzel RR, Littke T, Kuranoff S, et al; SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol. 2009 Mar;20(3):655-664, Epub 2009 Jan 14.
13. Mishra R, Emancipator SN, Kern TS, Simonson MS. Association between endothelin-1 and collagen deposition in db/db diabetic mouse kidneys. Biochem Biophys Res Commun. 2006 Jan 6; 339(1):65-70. Epub 2005 Nov 8.
14. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009 Aug;15(8):940-945. Epub 2009 Jul 26.
15. Wang J, Shi GP. Mast cell stabilization: novel medication for obesity and diabetes. Diabetes Metab Res Rev. 2011 Nov;27(8): 919-924.
16. Xu JM, Shi GP. Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev. 2012 Feb; 33(1):71-108. Epub 2012 Jan 12.
17. Zhang J, Shi GP. Mast cells and metabolic syndrome. Biochim Biophys Acta. 2012 Jan;1822(1):14-20. Epub 2010 Dec 23.
18. Ritz E. Chymase: a potential culprit in diabetic nephropathy? J Am Soc Nephrol. 2003 Jul;14(7):1952-1954.
19. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003 Jul;14(7):1738-1747.
20. Konishi Y, Morikawa T, Okada N, et al. Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan. Hypertens Res. 2008 Aug;31(8):1517-1524.
21. Sakamoto-Ihara T, Suzuki Y, Kurusu A, et al. Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy. Inflamm Res. 2007 Oct;56(10):421-427.
22. McPherson EA, Luo Z, Brown RA, et al. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2004 Feb;15(2): 493-500.
23. Welker P, Krämer S, Groneberg DA, et al. Increased mast cell number in human hypertensive nephropathy. Am J Physiol Renal Physiol. 2008 Oct;295(4):F1103-F1109. Epub 2008 Aug 6.
24. Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation. 1999 Aug 10;100(6):654-658.
25. Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci. 2006;100(5):391-397.
26. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther. 2006 Dec; 112(3):668-676. Epub 2006 Jul 11.
27. Reilly CF, Tewksbury DA, Schechter NM, Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem. 1982 Aug 10;257(15):8619-8622.
28. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990 Dec 25;265(36):22348-22357. Erratum in: J Biol Chem. 1991 Jun 25;266(18):12114.
29. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res. 2007 Aug 31;101(5):455-464. Epub 2007 Jul 12.
30. Ju H, Gros R, You X, et al. Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13): 7469-7474.
31. Maeda Y, Inoguchi T, Takei R, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol. 2010 Dec; 299(6):F1328-F1338. Epub 2010 Sep 29.
32. Scandiuzzi L, Beghdadi W, Daugas E, et al. Mouse mast cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune complex-mediated glomerulonephritis. J Immunol. 2010 Jul 1;185(1):624-633. Epub 2010 Jun 7.
33. Zheng JM, Yao GH, Cheng Z, Wang R, Liu ZH. Pathogenic role of mast cells in the development of diabetic nephropathy: a study of patients at different stages of the disease. Diabetologia. 2012 Mar;55(3):801-811. Epub 2011 Dec 1.
34. Yanagisawa H, Hammer RE, Richardson JA, et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest. 2000 May;105(10):1373-1382.
35. Harrison-Bernard LM, Cook AK, Oliverio MI, Coffman TM. Renal segmental microvascular responses to ANG II in AT1A receptor null mice. Am J Physiol Renal Physiol. 2003 Mar;284(3):F538-F545. Epub 2002 Nov 12.
36. Park S, Bivona BJ, Feng Y, Lazartigues E, Harrison-Bernard LM. Intact renal afferent arteriolar autoregulatory responsiveness in db/db mice. Am J Physiol Renal Physiol. 2008 Nov;295(5): F1504-F1511. Epub 2008 Aug 27.
37. Park S, Bivona BJ, Kobori H, et al. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol. 2010 Jan;298(1):F37-F48. Epub 2009 Oct 21.
38. Schneider MP, Inscho EW, Pollock DM. Attenuated vasoconstrictor responses to endothelin in afferent arterioles during a high-salt diet. Am J Physiol Renal Physiol. 2007 Apr; 292(4):F1208-F1214. Epub 2007 Jan 9.
39. Watts SW, Thakali K, Smark C, Rondelli C, Fink GD. Big ET-1 processing into vasoactive peptides in arteries and veins. Vascul Pharmacol. 2007 Nov-Dec;47(5-6):302-312. Epub 2007 Sep 7.
40. Simard E, Jin D, Takai S, et al. Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther. 2009 Feb;328(2):540-548. Epub 2008 Nov 5.
41. Zoja C, Cattaneo S, Fiordaliso F, et al. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol. 2011 Nov;301(5):F1114-F1123. Epub 2011 Aug 3.
42. Mann JFE, Green D, Jamerson K, et al; ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010 Mar;21(3):527-535. Epub 2010 Feb 18.